Last reviewed · How we verify
NCT06846996: RECOVER
Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
trial testing Trastuzumab deruxtecan (T-DXd) in HER2-positive Gastric Cancer in 260 participants. Currently enrolling.
31 July 2027
Quick facts
| Lead sponsor | Daiichi Sankyo |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 260 |
| Start date | 27 February 2025 |
| Primary completion | 31 July 2027 |
| Estimated completion | 31 July 2027 |
| Sites | 36 locations across China |
Drugs / interventions tested
- Trastuzumab deruxtecan (T-DXd) — full drug profile →
Conditions studied
- HER2-positive Gastric Cancer — all drugs for HER2-positive Gastric Cancer →
- HER2-positive Gastroesophageal Junction — all drugs for HER2-positive Gastroesophageal Junction →
Sponsor
Daiichi Sankyo — full company profile →
Who can join
18 and older, any sex, with HER2-positive Gastric Cancer or HER2-positive Gastroesophageal Junction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Trastuzumab deruxtecan's (T-DXd's) efficacy and safety has been confirmed in traditional clinical trials, there is a lack of real-world evidence, especially among Chinese patients. The objective of this study is to evaluate real-world effectiveness and safety profile of T-DXd by collecting real-world data treating in patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06846996
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Trastuzumab deruxtecan (T-DXd)
Trials testing the same drug.
- NCT06585969 — A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastat · Phase 3 · withdrawn
- NCT06797622 — Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast C · Phase 2 · not yet recruiting
- NCT03529110 — DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breas · Phase 3 · active not recruiting
Other recruiting trials for HER2-positive Gastric Cancer
Currently open trials in the same condition.
- NCT06764875 — A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treat · Phase 3 · recruiting
- NCT06414733 — HER-2 B Cell Peptide Vaccine · Phase 1 · recruiting
- NCT06532006 — A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal · Phase 3 · recruiting
- NCT06730373 — First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) · Phase 2 · recruiting
- NCT06572319 — Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens · Phase 1, PHASE2 · recruiting
Other Daiichi Sankyo trials
Trials by the same sponsor.
- NCT07474649 — A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events · Phase 3 · not yet recruiting
- NCT07206472 — A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholestero · active not recruiting
- NCT07220616 — A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies · Phase 1, PHASE2 · recruiting
- NCT07268625 — Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorv · Phase 1 · completed
- NCT07244341 — A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer ( · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06846996 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Daiichi Sankyo
- Last refreshed: 8 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06846996.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing